Abbisko and AstraZeneca advance lung cancer drug combo trial
- Abbisko Therapeutics and AstraZeneca (NYSE:AZN) agreed to develop a combination therapy for EGFR-mutated, PD-L1 positive non-small cell lung cancer.
- The plan includes a Phase I/II clinical trial combining lumipodlin (ABSK043) with TAGRISSO (osimertinib).
- China’s NMPA cleared the investigational new drug application on May 20, 2026.
Abbisko Therapeutics and AstraZeneca (NYSE:AZN) entered a strategic collaboration to develop a combination therapy for patients with EGFR-mutated, PD-L1 positive non-small cell lung cancer (NSCLC).
The agreement focuses on testing Abbisko’s oral PD-L1 inhibitor lumipodlin (ABSK043) alongside AstraZeneca’s targeted cancer drug TAGRISSO (osimertinib) in a multicenter Phase I/II clinical trial.
China’s National Medical Products Administration cleared the investigational new drug application for the combination on May 20, 2026, enabling clinical development to proceed.
Abbisko will lead the Phase II portion of the study, while both Abbisko and AstraZeneca will share responsibilities across the broader trial program.
The collaboration aims to evaluate whether combining immune-oncology and targeted kinase inhibition can improve outcomes in a defined lung cancer subgroup.
Abbisko continues to expand its oncology pipeline through partnerships with global pharmaceutical companies.
AstraZeneca continues to develop TAGRISSO as a cornerstone therapy in EGFR-mutated lung cancer across multiple combination strategies.
FAQ
SEO section
Slug:
Meta title:
